• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aerovate Therapeutics Inc.

    2/9/24 4:28:55 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTE alert in real time by email
    SC 13G 1 d778996dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Aerovate Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    008064107

    (CUSIP Number)

    June 16, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 008064107    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    TCG Crossover GP I, LLC

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    2,201,274 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    2,201,274 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,201,274 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.0% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1)

    Consists of 2,201,274 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover I (as defined in Item 2(a) below). TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 27,668,887 shares of Common Stock outstanding as of November 9, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (the “Commission”) on November 13, 2023 (the “Form 10-Q”).


    CUSIP No. 008064107    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    TCG Crossover Fund I, L.P.

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    2,201,274 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    2,201,274 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,201,274 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.0% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    Consists of 2,201,274 shares of Common Stock of the Issuer held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 27,668,887 shares of Common Stock outstanding, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 008064107    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    Chen Yu

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    2,201,274 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    2,201,274 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,201,274 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.0% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1)

    Consists of 2,201,274 shares of Common Stock of the Issuer held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 27,668,887 shares of Common Stock outstanding, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 008064107    13G

     

    Item 1(a).

    Name of Issuer:

    Aerovate Therapeutics, Inc. (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    930 Winter Street, Suite M-500

    Waltham, MA 02451

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (“TCG Crossover I”), TCG Crossover GP I, LLC (“TCG Crossover GP I” and together with TCG Crossover I, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    008064107

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 008064107    13G

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 008064107    13G

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not Applicable

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 008064107    13G

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

     

    TCG Crossover Fund I, L.P.
    By:   TCG Crossover GP I, LLC
    Its:   General Partner
    By:   /s/ Chen Yu
      Managing Member
    TCG Crossover GP I, LLC
    By:   /s/ Chen Yu
      Managing Member
    /s/ Chen Yu
    Chen Yu

     

    Get the next $AVTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTE

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AVTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fairmount Funds Management Llc

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:16:57 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lavelle Erin

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:15:30 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klein Lawrence Otto

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:10:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    SEC Filings

    See more
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/1/25 4:22:23 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

      SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

      4/30/25 4:51:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/29/25 4:05:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

      WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,

      3/6/24 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

      WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly

      7/11/23 5:00:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

      WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g

      1/23/23 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aerovate Therapeutics Inc.

      SC 13G/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      11/14/24 4:21:04 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aerovate Therapeutics Inc.

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      6/20/24 6:00:09 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aerovate Therapeutics Inc. (Amendment)

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/30/24 4:16:13 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

      Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

      6/21/24 3:23:59 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Financials

    Live finance-specific insights

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

      4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

      6/20/24 5:56:07 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerovate Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously

      6/18/24 7:32:31 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by TD Cowen

      TD Cowen downgraded Aerovate Therapeutics from Buy to Hold

      6/18/24 7:23:55 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously

      6/18/24 7:22:03 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care